Dr Neal Shore speaks to ecancer about patient preferences for treatment of non-metastatic hormone-sensitive prostate cancer (nmHSPC).

This discrete choice experiment evaluated treatment preferences among patients with nonmetastatic hormone-sensitive prostate cancer across nine countries.

The vast majority of patients preferred androgen receptor pathway inhibitor–based therapy with or without androgen deprivation therapy over androgen deprivation therapy alone.

The most influential factor driving treatment choice was metastasis-free survival, followed by the risk of hot flashes and maintenance of sexual interest.

These findings suggest that patients prioritise treatments that balance effectiveness, side effects, and quality of life, supporting a more personalised approach to treatment decision-making.